Jump to content

Roland Mertelsmann

From Wikipedia, the free encyclopedia

Roland Mertelsmann
Born (1944-10-05) 5 October 1944 (age 80)
Hameln, Germany
Known forHematology, oncology, gene therapy, stem cell transplantation
Scientific career
FieldsOncology, hematology
InstitutionsUniversity of Freiburg

Roland Mertelsmann (born 5 October 1944) is a German hematologist and oncologist. He was a professor at the Freiburg University Medical Center, Department of Internal Medicine I (Oncology/Hematology). Mertelsmann is known for his scientific works in the fields of hematology, oncology, gene therapy and stem cell transplantation.

Biography

[edit]

Mertelsmann studied medicine at the University of Göttingen 1966–68. He was a doctoral candidate at the Max Planck Institute for Experimental Medicine at Heinrich Matthaei in Göttingen 1966–68. He continued his medical education at the School of Medicine King's College London and at the Columbia-Presbyterian Medical Center, New York 1968–78. After graduating from Hamburg University Medical School and receiving his MD degree, he became Research Fellow at the Department of Developmental Hematopoiesis and received a special fellowship in Hematology and Clinical Oncology at Memorial Sloan-Kettering Cancer Center (MSKCC), 1976–78. There he contributed to the isolation of the blood stimulating growth factor G-CSF, which leads to a faster recovery of white blood cells after chemotherapy and radiation therapy protecting patients better against severe infections. From 1978 to 86 he was clinical assistant physician at MSKCC, then assistant attending physician and associate attending physician at the Memorial Hospital of Sloan-Kettering Cancer Center. He was promoted from assistant professor of medicine to associate professor of medicine at Cornell University, New York. In 1985, he returned to Germany and was appointed professor and head of the 3rd Medical Clinic Hematology and Oncology at the University of Mainz, Germany, University Medical Center. 1989 he accepted a professorship at the University of Freiburg. At Freiburg University Medical Center he became the director of the Department for Medicine I, Oncology, Hematology and Stem Cell Transplantation. He retired in 2012.[1]

During his career Mertelsmann recruited and promoted young scientists. Several leading positions at universities and in the industry were occupied with former team members of Mertelsmann. In 2008 he founded the International Master Program in Biomedical Sciences,[2] a cooperation of the universities of Freiburg and Buenos Aires, educating and training international master students in biomedicine. In 2014 he initiated the foundation of the journal JOSHA,[3] a novel internet platform to access the broad diversity of important discoveries and creativity in the fields of science, humanities and arts. Mertelsmann published more than 400 articles in medical journals.[citation needed]

Scientific contribution

[edit]

Molecular and cellular mechanisms of malignancy- First description of a human RNA polymerase

[edit]

After discovery of the genetic code by Heinrich Matthaei and Marshall Nirenberg (1962), Mertelsmann began his research for his medical doctorate as a medical student in Heinrich Matthaei's Laboratory at the Max-Planck-Institute for experimental Medicine in Göttingen, Germany, demonstrating and characterizing for the first time a human RNA-Polymerase.[4] Since nucleic acid synthesis is an important target for chemotherapeutic agents, he subsequently investigated in his team together with various colleagues, DNA-Polymerases, especially terminal deoxynucleotidyl transferase (TdT), and RNA-Polymerases as diagnostic and prognostic markers in leukemias and lymphomas.[5]

Studies of the Pathophysiology and Molecular Biology of Cancer Cells

[edit]

The “Plasticity” of hematopoietic stem cells (HSC), i.e. the differentiation of HSC into cells of other organs,[6] was intensively studied with Alexandros Spyridonidis[7] in patients after allogeneic bone marrow transplantation. These studies demonstrated conclusively, that this phenomenon can be observed in these patients, but is a rare event. Molecular mechanisms of B-cell neoplasias[8][9] were investigated together with Binder, Trepel and Dierks, the pathogenic significance of granulocytes in Graft-versus-host disease with Zeiser and his colleagues.[10]

Clinical Significance of the Leukemia Phenotype

[edit]

As a member of the clinical (Director Bayard Clarkson) and laboratory teams (Director Malcolm A.S. Moore), he carried out a systematic analysis of all patients with acute myeloid leukemia (AML) treated at MSKCC, defining the prognostic and predictive parameters of cell cytology, cell growth in vitro and enzymatic markers.[11][12] By using all techniques available at the time for phenotypic characterization of leukemia cells, he was successful in discovering and describing novel subentities of acute leukemias.[13][14]

New therapeutic Modalities

[edit]

In Cooperation with Karl Welte and his colleagues at MSKCC the purification and molecular and biological characterization of cytokines, important regulators of cell division, differentiation and migration, were the focus of his work in the following years at MSKCC. Interleukin-2[15] as well as G-CSF[16] were purified to homogeneity, First translational and clinical studies of cytokines followed.[17] Since experiments in murine models demonstrated that local production by gene transduced cells produced a stronger and more specific immune response than a systemic application, e.g. of Interleukin-2, this strategy was also pursued by his group in Phase I clinical trials.[18][19][20] These studies contributed to the later, successful clinical implementation of gene therapy for this and other indications.[citation needed]

Clinical Studies

[edit]

In clinical trials for patients with leukemias and lymphomas at the MSKCC[21] and subsequently in German and European clinical trial groups,[22][23] new therapeutic concepts were studied including classical chemotherapies as well as novel therapeutic strategies.[24][25] For some rare, generally lethal cancers, the innovative use of rapidly recycling classical chemotherapy combinations followed by immediate High Dose Chemotherapy with HSC transplantation, led to long term remission and probably cures, which had not been seen with other therapies and in historical controls.[26]

As clinical oncologist Mertelsmann also search for novel strategies to not only prolong life, but to increase quality of life. The systematic development of aerobic training programs for cancer patients undergoing chemotherapy and bone morrow transplantation[27] was highly successful and is now being used in many cancer centers worldwide.[citation needed]

Accusation of scientific misconduct

[edit]

Mertelsmann was involved in a scientific misconduct affair in 1997. The complaint focussed on the falsification of laboratory data. An investigation commission did not prove the active participation of Mertelsmann.[28]

Academic memberships

[edit]

Mertelsmann is or was member of many international scientific organizations or journals, among them many years at the journals European Journal of Cancer and Annals of Hematology. He is a foundation member of the Comprehensive Cancer Center Freiburg (CCCF), Initiator and director of the International Biomedical Exchange Program (IMEP), founder of the ARGER-Foundation,[29] editor of the SRC-SDARF-UJDRF Joint Programme in Stem Cell Research, Stockholm and president of the International Association for Comparative Research on Leukemia and related Diseases (IACRLD).[citation needed]

Other select memberships:

Awards

[edit]
  • 1976 Konjetzny Prize for Cancer Research[1]
  • 1980 Vincenz Czerny Award for Cancer Research (DGHO)
  • 1982 Boyer Award for Clinical Investigation (MSKCC)
  • 1985 Warner Award for Cancer Research (Warner Foundation)
  • 1990 Hamilton-Farley Award (ESMO)
  • 2000 Excellency Award, 13th International Symposium, Molecular Biology of Hematopoiesis, New York City
  • 2005 Professor honoris causa, Universidad del Salvador, Buenos Aires, Argentinien
  • 2007 Doctor honoris causa, University "Gr. T. Popa", Iasi, Rumänien
  • 2008 Professor honoris causa, Universidad de Buenos Aires (UBA), Buenos Aires, Argentinien
  • 2011 Doctor honoris causa, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina[1]

Publications

[edit]

Articles in journals

Books (selectionl)

  • Das Blaue Buch: Chemotherapie-Manual Hämatologie und Internistische Onkologie. 5. Auflage. Springer Medizin, Berlin 2014, ISBN 978-3-642-41740-5.
  • Das Rote Buch: Hämatologie und Internistische Onkologie. 5., überarb. und erw. Auflage. ecomed Medizin, Heidelberg 2014, ISBN 978-3-609-51217-4.
  • mit Monika Engelhardt: Perspektiven einer zukünftigen Medizin und eines sich wandelnden Arztbildes. Rombach 2008, ISBN 978-3-7930-5038-4.
  • Leukämien und maligne Lymphome. Thieme, Stuttgart 1981.
  • mit Monika Engelhardt, Dietmar P. Berger und Philippe Moreau (eds.): Précis d'hématologie et d'oncologie. Springer, Paris 2011, ISBN 978-2-287-99341-1.
[edit]

See also

[edit]

Roland Mertelsmann in:

References

[edit]
  1. ^ a b c Roland Mertelsmann CV
  2. ^ IMBS
  3. ^ JOSHA
  4. ^ R. Mertelsmann: Purification and some properties of a soluble DNA-dependent. RNA polymerase from nuclei of human placenta. In: Eur. J. Biochem. 1969 Jun;9(3), S. 311–318. PMID 5795512
  5. ^ R. Mertelsmann, B. Koziner, D. A. Filippa, E. Grossbard, G. Incefy, M. A. Moore, B. D. Clarkson: Clinical significance of TdT, cell surface markers and CFU-C in 297 patients with hematopoietic neoplasias. In: Haematol Blood Transfus. 1979;23, S. 131–138. PMID 317470. Prof. em. Dr. Drs. h.c. Roland Mertelsmann
  6. ^ R. Mertelsmann: Plasticity of bone marrow-derived stem cells. In: J Hematother Stem Cell Res. 2000 Dec;9(6), S. 957–960. Review. PMID 11177610
  7. ^ A. Spyridonidis, R. Mertelsmann, J. Finke: Hematopoietic stem cell transplantation: more than just hematopoietic? In: J Cancer Res Clin Oncol. 2004 Mar;130(3), S. 127–134. Epub 2004 Jan 16. Review. PMID 14727105
  8. ^ M. Binder, F. Müller, M. Frick, C. Wehr, F. Simon, B. Leistler, H. Veelken, R. Mertelsmann, M. Trepel: CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. In: Blood. 2013 Jan 3;121(1), S. 239–241. doi:10.1182/blood-2012-09-454439. PMID 23287626
  9. ^ C. Dierks, J. Grbic, K. Zirlik, R. Beigi, N. P. Englund, G. R. Guo, H. Veelken, M. Engelhardt, R. Mertelsmann, J. F. Kelleher, P. Schultz, M. Warmuth: Essential role of stromally induced hedgehog signaling in B-cell malignancies. In: Nat Med. 2007 Aug;13(8), S. 944–951. Epub 2007 Jul 15. PMID 17632527.
  10. ^ L. Schwab, L. Goroncy, S. Palaniyandi, S. Gautam, A. Triantafyllopoulou, A. Mocsai, W. Reichardt, F. J. Karlsson, S. V. Radhakrishnan, K. Hanke, A. Schmitt-Graeff, M. Freudenberg, F. D. von Loewenich, P. Wolf, F. Leonhardt, N. Baxan, D. Pfeifer, O. Schmah, A. Schönle, S. F. Martin, R. Mertelsmann, J. Duyster, J. Finke, M. Prinz, P. Henneke, H. Häcker, G. C. Hildebrandt, G. Häcker, R. Zeiser: Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. In: Nat Med. 2014 Jun;20(6), S. 648–654. doi:10.1038/nm.3517. Epub 2014 May 18. PMID 24836575
  11. ^ R. Mertelsmann, M. A. Moore, B. Clarkson: Leukemia cell phenotype and prognosis: an analysis of 519 adults with acute leukemia. In: Blood Cells. 1982;8(3), S. 561–583. PMID 6984348
  12. ^ R. Mertelsmann, H. Tzvi Thaler, L. To, T. S. Gee, S. McKenzie, P. Schauer, A. Friedman, Z. Arlin, C. Cirrincione, B. Clarkson: Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. In: Blood. 1980 Nov;56(5), S. 773–781. PMID 6932977.
  13. ^ N. Ciobanu, M. Andreeff, B. Safai, B. Koziner, R. Mertelsmann: Lymphoblastic neoplasia in a homosexual patient with Kaposi’s sarcoma. In: Ann Intern Med. 1983 Feb;98(2), S. 151–155. PMID 6572044.
  14. ^ R. Mertelsmann, B. Koziner, R. Ralph, D. Filippa, S. McKenzie, Z. A. Arlin, T. S. Gee, M. A. Moore, B. D. Clarkson: Evidence for distinct lymphocytic and monocytic populations in a patient with terminal transferase—positive acute leukemia. In: Blood. 1978 Jun;51(6), S. 1051–1056. PMID 274159
  15. ^ K. Welte, C. Y. Wang, R. Mertelsmann, S. Venuta, S. P. Feldman, M. A. Moore: Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. In: J Exp Med. 1982 Aug 1;156(2), S. 454–464. PMID 6980256 PMC 2186775
  16. ^ K. Welte, E. Platzer, L. Lu, J. L. Gabrilove, E. Levi, R. Mertelsmann, M. A. Moore: Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. In: Proc Natl Acad Sci U S A. 1985 Mar;82(5), S. 1526–1530. PMID 3871951 PMC 397296
  17. ^ R. Mertelsmann, K. Welte, C. Sternberg, R. O'Reilly, M. A. Moore, B. D. Clarkson, H. F. Oettgen: Treatment of immunodeficiency with interleukin-2: initial exploration. In: J Biol Response Mod. 1984 Oct;3(5), S. 483–490. PMID 6334136
  18. ^ H. Glimm, K. Flügge, D. Möbest, V. M. Hofmann, J. Postmus, R. Henschler, W. Lange, J. Finke, H. P. Kiem, G. Schulz, F. Rosenthal, R. Mertelsmann, C. von Kalle: Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium. In: Hum Gene Ther. 1998 Apr 10;9(6), S. 771–778. PMID 9581900.
  19. ^ H. Veelken, A. Mackensen, M. Lahn, G. Köhler, D. Becker, B. Franke, U. Brennscheidt, P. Kulmburg, F. M. Rosenthal, H. Keller, J. Hasse, W. Schultze-Seemann, E. H. Farthmann, R. Mertelsmann, A. Lindemann: A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. In: Int J Cancer. 1997 Jan 27;70(3), S. 269–277. PMID 9033626
  20. ^ G. Stingl, E. B. Brŏcker, R. Mertelsmann, K. Wolff, S. Schreiber, E. Kămpgen, A. Schneeberger, W. Dummer, U. Brennscheid, H. Veelken, M. L. Birnstiel, K. Zatloukal, W. Schmidt, G. Maass, E. Wagner, M. Baschle, M. Giese, E. R. Kempe, H. A. Weber, T. Voigt: Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. In: Hum Gene Ther. 1996 Mar 1;7(4), S. 551–563. PMID 8800750
  21. ^ R. Mertelsmann, R. L. Drapkin, T. S. Gee, S. Kempin, S. Passe, H. T. Thaler, Z. Arlin, M. Dowling, P. Dufour, S. McKenzie, L. To, E. Comacho, H. F. Oettgen, J. H. Burchenal, B. Clarkson: Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol. In: Cancer. 1981 Nov 15;48(10), S. 2136–2142. PMID 6170414
  22. ^ M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits, M. Mohren, E. Lengfelder, M. Reiser, C. Nickenig, M. Clemens, N. Peter, C. Bokemeyer, H. Eimermacher, A. Ho, M. Hoffmann, R. Mertelsmann, L. Trümper, L. Balleisen, R. Liersch, B. Metzner, F. Hartmann, B. Glass, V. Poeschel, N. Schmitz, C. Ruebe, A. C. Feller, M. Loeffler: German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). In: Lancet Oncol. 2008 Feb;9(2), S. 105–116. doi:10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. PMID 18226581
  23. ^ O. Determann, E. Hoster, G. Ott, H. Wolfram Bernd, C. Loddenkemper, M. Leo Hansmann, T. E. Barth, M. Unterhalt, W. Hiddemann, M. Dreyling, W. Klapper: European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. In: Blood. 2008 Feb 15;111(4), S. 2385–2387. Epub 2007 Dec 12. PMID 18077791
  24. ^ H. P. Koeffler, D. Heitjan, R. Mertelsmann, J. E. Kolitz, P. Schulman, L. Itri, P. Gunter, E. Besa: Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. In: Blood. 1988 Mar;71(3), S. 703–708. PMID 3278754. 309: W. Hiddemann, H. Kreutzmann, K. Straif, W. D. Ludwig, R. Mertelsmann, M. Planker, R. Donhuijsen-Ant, E. Lengfelder, Z. Arlin, T. Büchner: High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. In: Semin Oncol. 1987 Jun;14(2 Suppe 1), S. 73–77. PMID 3473685
  25. ^ E. J. Gold, R. H. Mertelsmann, L. M. Itri, T. Gee, Z. Arlin, S. Kempin, B. Clarkson, M. A. Moore: Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. In: Cancer Treat Rep. 1983 Nov;67(11), S. 981–986. PMID 6580071
  26. ^ L. Houet, I. Möller, M. Engelhardt, G. Köhler, H. Schmidt, D. Herchenbach, M. Schnitzler, A. Schmitt-Graeff, A. A. Jungbluth, R. Mertelsmann, B. Rumstadt, C. F. Waller: Long-term remission after CD34+-selected PBSCT in a patient with advanced intra-abdominal desmoplastic small round-cell tumor. In: Bone Marrow Transplant. 2010 Apr;45(4), S. 793–795. doi:10.1038/bmt.2009.226. Epub 2009 Aug 31. PMID 19718066 PMC 3147145
  27. ^ F. Dimeo, H. Bertz, J. Finke, S. Fetscher, R. Mertelsmann, J. Keul: An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. In: Bone Marrow Transplant. 1996 Dec;18(6), S. 1157–1160. PMID 8971388.
  28. ^ Klaus Koch: Fälschungsskandal – Verjährt und zugenäht. auf: aerzteblatt.de
  29. ^ ARGER Foundation
Retrieved from "https://en.wikipedia.org/w/index.php?title=Roland_Mertelsmann&oldid=1207186159"